Evidence map›Paper›PMID 33596235›Full record

ArticlePloS one2021

Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase.

Matthew R Freidel, Roger S Armen

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Investigating novel thiazolyl-indazole derivatives as scaffolds for SARS-CoV-2 MEuropean journal of medicinal chemistry reports · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew R FreidelDepartment of Pharmaceutical Sciences, College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.
Roger S ArmenDepartment of Pharmaceutical Sciences, College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0003-3830-1450

Funding

Project 4 - OGR1- and TSPO- dependent mechanisms mediated by benzodiazepines affecting ASM contractionP01HL114471 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LIGGETT, STEPHEN B · 2013 to 2023
$23.9M
Targeting the PTH1R Signaling Pathway for Osteoarthritis Therapy by a Novel Disruptor PeptideR01AR077666 · NIAMS · THOMAS JEFFERSON UNIVERSITY · PI WANG, BIN · 2020 to 2024
$1.7M
NHLBI NIH HHS P01 HL114471NIAMS NIH HHS R01 AR077666NIH HHS 1P01HL114471-06
6 · The paper itself

Abstract

The 2019 emergence of, SARS-CoV-2 has tragically taken an immense toll on human life and far reaching impacts on society. There is a need to identify effective antivirals with diverse mechanisms of action in order to accelerate preclinical development. This study focused on five of the most established drug target proteins for direct acting small molecule antivirals: Nsp5 Main Protease, Nsp12 RNA-dependent RNA polymerase, Nsp13 Helicase, Nsp16 2'-O methyltransferase and the S2 subunit of the Spike protein. A workflow of solvent mapping and free energy calculations was used to identify and characterize favorable small-molecule binding sites for an aromatic pharmacophore (benzene). After identifying the most favorable sites, calculated ligand efficiencies were compared utilizing computational fragment screening. The most favorable sites overall were located on Nsp12 and Nsp16, whereas the most favorable sites for Nsp13 and S2 Spike had comparatively lower ligand efficiencies relative to Nsp12 and Nsp16. Utilizing fragment screening on numerous possible sites on Nsp13 helicase, we identified a favorable allosteric site on the N-terminal zinc binding domain (ZBD) that may be amenable to virtual or biophysical fragment screening efforts. Recent structural studies of the Nsp12:Nsp13 replication-transcription complex experimentally corroborates ligand binding at this site, which is revealed to be a functional Nsp8:Nsp13 protein-protein interaction site in the complex. Detailed structural analysis of Nsp13 ZBD conformations show the role of induced-fit flexibility in this ligand binding site and identify which conformational states are associated with efficient ligand binding. We hope that this map of over 200 possible small-molecule binding sites for these drug targets may be of use for ongoing discovery, design, and drug repurposing efforts. This information may be used to prioritize screening efforts or aid in the process of deciphering how a screening hit may bind to a specific target protein.

Indexed as

Allosteric SiteAntiviral AgentsBinding SitesComputational BiologyCoronavirus 3C ProteasesCoronavirus RNA-Dependent RNA PolymeraseCOVID-19COVID-19 Drug TreatmentHumansMethyltransferasesModels, MolecularMolecular Targeted TherapyProtein BindingRNA-Dependent RNA PolymeraseRNA HelicasesSARS-CoV-23C-like protease, SARS coronavirusAntiviral AgentsCoronavirus 3C ProteasesCoronavirus RNA-Dependent RNA PolymeraseMethyltransferasesNSP12 protein, SARS-CoV-2Nsp13 protein, SARS-CoVNSP16 protein, SARS-CoV-2RNA-Dependent RNA PolymeraseRNA HelicasesViral Nonstructural Proteins

Identifiers

PMID33596235
PMCPMC7888625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.